296 related articles for article (PubMed ID: 29947751)
1. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.
Goette A; Kwong WJ; Ezekowitz MD; Banach M; Hjortshoj SP; Zamoryakhin D; Lip GYH
Europace; 2018 Dec; 20(12):1936-1943. PubMed ID: 29947751
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
[TBL] [Abstract][Full Text] [Related]
4. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
5. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
[TBL] [Abstract][Full Text] [Related]
7. Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.
Goette A; Merino JL; De Caterina R; Huber K; Heidbuchel H; Jin J; Lip GYH
Clin Res Cardiol; 2020 Nov; 109(11):1374-1380. PubMed ID: 32236718
[TBL] [Abstract][Full Text] [Related]
8. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
Kozieł M; Merino JL; De Caterina R; Huber K; Jin J; Melino M; Goette A; Lip GYH;
Eur J Clin Invest; 2020 May; 50(5):e13221. PubMed ID: 32150758
[TBL] [Abstract][Full Text] [Related]
9. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
Blann AD; Boriani G; Lip GY
Europace; 2016 Oct; 18(10):1507-1513. PubMed ID: 27876695
[TBL] [Abstract][Full Text] [Related]
10. Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.
Merino JL; Lip GYH; Heidbuchel H; Cohen AA; De Caterina R; de Groot JR; Ezekowitz MD; Le Heuzey JY; Themistoclakis S; Jin J; Melino M; Winters SM; Merkely B; Goette A
Europace; 2019 Nov; 21(11):1633-1638. PubMed ID: 31436835
[TBL] [Abstract][Full Text] [Related]
11. Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF).
Lip GYH; Merino JL; Banach M; de Groot JR; Maier LS; Themistoclakis S; Boriani G; Jin J; Melino M; Winters SM; Goette A
Am J Cardiol; 2019 Feb; 123(4):592-597. PubMed ID: 30527775
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban: a review in nonvalvular atrial fibrillation.
McCormack PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
[TBL] [Abstract][Full Text] [Related]
14. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GYH; Al-Saady N; Ezekowitz MD; Banach M; Goette A
Am Heart J; 2017 Nov; 193():16-22. PubMed ID: 29129251
[TBL] [Abstract][Full Text] [Related]
15. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
Plitt A; Ezekowitz MD; De Caterina R; Nordio F; Peterson N; Giugliano RP;
Clin Cardiol; 2016 Jun; 39(6):345-6. PubMed ID: 27028520
[No Abstract] [Full Text] [Related]
16. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
20. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
